Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees

Core Points - Celularity Inc. has been notified by Nasdaq regarding non-payment of fees and potential delisting unless an appeal is made [1] - The company has a past due fee balance of $70,000, which was paid in full on April 25, 2025 [1] - Nasdaq also indicated that Celularity is delinquent in filing its Form 10-K for the year ended December 31, 2024, which could lead to additional delisting actions [2] - The company is actively working to file the 2024 Form 10-K and expects to do so imminently [3] Company Overview - Celularity Inc. is a regenerative and cellular medicine company focused on developing and commercializing advanced biomaterial products and placental-derived cell therapies [4] - The company aims to leverage the unique biology of the placenta to create therapeutic solutions that meet significant global healthcare needs [4]